308 results on '"Kameoka, Yoshihiro"'
Search Results
2. A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial)
3. Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia
4. Prognostic impact of peripheral blood WT1 mRNA dynamics in patients with acute myeloid leukemia treated with venetoclax combination therapy
5. Outcomes of adult patients with early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL) and non-ETP T-ALL
6. High baseline total lesion glycolysis predicts early progression of disease within 24 months in patients with high-tumor-burden follicular lymphoma
7. Safe administration and pharmacokinetic monitoring of crushed venetoclax tablets with posaconazole and clarithromycin via percutaneous endoscopic gastrostomy tube in a patient with acute myeloid leukemia
8. A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan
9. Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy
10. Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
11. The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration
12. Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy
13. Ponatinib Improved the Prognosis of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Japanese Single-Center Cohort Study
14. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial
15. Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin
16. Relationship between clinical course of nivolumab-related myositis and immune status in a patient with Hodgkin’s lymphoma after allogeneic hematopoietic stem cell transplantation
17. Safety and efficacy of high-dose ranimustine (MCNU) containing regimen followed by autologous stem cell transplantation for diffuse large B-cell lymphoma
18. Long‐term follow‐up after R‐High CHOP / CHASER / LEED with Auto‐PBSCT in untreated mantle cell lymphoma—Final analysis of JCOG0406
19. Supplementary Table S1 from Identification of CCND3 and BYSL as Candidate Targets for the 6p21 Amplification in Diffuse Large B-Cell Lymphoma
20. Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku Hematology Forum
21. Effects of ABCB1 polymorphisms on the transport of ponatinib into the cerebrospinal fluid in Japanese Philadelphia chromosome‐positive acute lymphoblastic leukaemia patients
22. Influence of UGT1A1 *6, *27, and *28 Polymorphisms on Nilotinib-induced Hyperbilirubinemia in Japanese Patients with Chronic Myeloid Leukemia
23. Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia
24. Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia
25. Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation
26. Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant‐ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105
27. Effects of ABCB1 polymorphisms on the transport of ponatinib into the cerebrospinal fluid in Japanese Philadelphia chromosome-positive acute lymphoblastic leukaemia patients
28. Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor‐1 inhibitor TM5614 combined with a tyrosine kinase inhibitor
29. Cooperative tracking in camera sensor networks with sliding mode control
30. CDR3-independent expansion of Vδ1 T lymphocytes in acquired chronic pure red cell aplasia
31. Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant‐ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105.
32. Long‐term follow‐up after R‐High CHOP/CHASER/LEED with Auto‐PBSCT in untreated mantle cell lymphoma—Final analysis of JCOG0406.
33. Analysis of clinical characteristics and prognostic factors for angioimmunoblastic T-cell lymphoma
34. Long‐term outcomes and central nervous system relapse in extranodal natural killer/T‐cell lymphoma
35. Thrombocytopenia Caused by a Tea Beverage of Taxus yunnanensis (Chinese Yew)
36. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer–cell lymphoma/leukemia
37. MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes
38. Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor‐1 inhibitor TM5614 combined with a tyrosine kinase inhibitor.
39. Cooperative tracking in camera sensor networks with sliding mode control.
40. Safety and efficacy of low-dose liposomal amphotericin B as empirical antifungal therapy for patients with prolonged neutropenia
41. P-126: The prognostic impact of the UK Myeloma Research Alliance Risk Profile in untreated patients with multiple myeloma who received melphalan, prednisolone, and bortezomib: an ad hoc analysis of JCOG1105
42. Safety and feasibility of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma: Verlag Dr. Kovac, ISBN: 978-3-8300-6328-5, 98,80 €
43. T-cell prolymphocytic leukemia in Japan: is it a variant?
44. Fatal hemorrhagic pneumonia caused by Stenotrophomanas maltophilia in a patient with non-Hodgkin lymphoma
45. Age-associated alteration of γδ T-cell repertoire and different profiles of activation-induced death of Vδ1 and Vδ2 T cells
46. Angioimmunoblastic T-cell lymphoma and membranous nephropathy: a still unreported association
47. Kidney-limited intravascular large B cell lymphoma: a distinct variant of IVLBCL?
48. MO12-5 Phase III trial of bendamustine plus rituximab for relapsed or refractory diffuse large B-cell lymphoma in Japan
49. Late-Onset Fatal Epstein-Barr Virus—Associated Hemophagocytic Syndrome Following Cord Blood Cell Transplantation for Adult Acute Lymphoblastic Leukemia
50. Single response assessment of transplant-ineligible multiple myeloma: a supplementary analysis of JCOG1105 (JCOG1105S1)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.